Esra Kaya Kiliç
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esra Kaya Kiliç has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Sami Kinikli
Sağlık Bilimleri Üniversitesi, Ankara Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara
19 shared publications - Salih Cesur
ANKARA EĞİTİM VE ARAŞTIRMA HASTANESİ, ENFEKSİYON HASTALIKLARI VE KLİNİK MİKROBİYOLOJİ
16 shared publications - Çiğdem Ataman Hatipoğlu
Sağlık Bilimleri Üniversitesi, Ankara Eğitim ve Araştırma Hastanesi
15 shared publications - Şerife Altun Demircan
Sağlık Bilimleri Üniversitesi Ankara Eğitim ve Araştırma Hastanesi
13 shared publications - Fatma Şebnem Erdinç
ANKARA EĞİTİM VE ARAŞTIRMA HASTANESİ, ENFEKSİYON HASTALIKLARI VE KLİNİK MİKROBİYOLOJİ
9 shared publications - Gunay Tuncer Ertem
ANKARA EĞİTİM VE ARAŞTIRMA HASTANESİ, ENFEKSİYON HASTALIKLARI VE KLİNİK MİKROBİYOLOJİ
9 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 28 (2) , 207-211
Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV
Aim: People living with HIV (PLWH) face a heightened risk of acquiring hepatitis B virus (HBV) infection because these two viruses share common transmission pathways. HIV/HBV coinfection is associated with accelerated liver disease progression. Consequently, hepatitis B vaccination is a critical preventive measure for PLWH. This study was designed to assess the serological response to hepatitis B vaccination in PLWH.Material and Methods: PLWH followed at the Infectious Diseases and Clinical Microbiology Clinic who were seronegative for HBsAg, anti-HBs, and anti-HBc IgG were retrospectively identified. Anti-HBs levels measured 1 month to 1 year after the final vaccine dose were assessed. Criteria associated with low response (anti-HBs titer: <100 mIU/mL) and high response (≥100 mIU/mL) were also evaluated.Results: A total of 54 patients were included in the final analysis. The median age was 43 (range, 22–80) years and 25.9% of the patients were female. Forty-nine patients (90.7%) had anti-HBs levels ≥10 mIU/mL. Anti-HBs levels ≥100 mIU/mL were observed in 10 (28.6%) patients who had received at least one double-dose vaccination versus 3 (15.8%) patients who had not (p=0.341), and in 18 (51.4%) patients with undetectable HIV RNA versus 5 (26.3%) patients with detectable HIV RNA (p=0.091), without reaching statistical significance.Conclusion: Adherence to the hepatitis B vaccination schedule was found to be suboptimal. Identifying the underlying causes of poor vaccination adherence and implementing strategies to improve compliance are essential in PLWH.
- 21 August 2026
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 28 (2) , 207-211
Open AccessEvaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV
Aim: People living with HIV (PLWH) face a heightened risk of acquiring hepatitis B virus (HBV) infection because these two viruses share common transmission pathways. HIV/HBV coinfection is associated with accelerated liver disease progression. Consequently, hepatitis B vaccination is a critical preventive measure for PLWH. This study was designed to assess the serological response to hepatitis B vaccination in PLWH.Material and Methods: PLWH followed at the Infectious Diseases and Clinical Microbiology Clinic who were seronegative for HBsAg, anti-HBs, and anti-HBc IgG were retrospectively identified. Anti-HBs levels measured 1 month to 1 year after the final vaccine dose were assessed. Criteria associated with low response (anti-HBs titer: <100 mIU/mL) and high response (≥100 mIU/mL) were also evaluated.Results: A total of 54 patients were included in the final analysis. The median age was 43 (range, 22–80) years and 25.9% of the patients were female. Forty-nine patients (90.7%) had anti-HBs levels ≥10 mIU/mL. Anti-HBs levels ≥100 mIU/mL were observed in 10 (28.6%) patients who had received at least one double-dose vaccination versus 3 (15.8%) patients who had not (p=0.341), and in 18 (51.4%) patients with undetectable HIV RNA versus 5 (26.3%) patients with detectable HIV RNA (p=0.091), without reaching statistical significance.Conclusion: Adherence to the hepatitis B vaccination schedule was found to be suboptimal. Identifying the underlying causes of poor vaccination adherence and implementing strategies to improve compliance are essential in PLWH.
- Open Access
Ocular Syphilis in the Era of Resurgence: Clinical Characteristics and Diagnostic Challenges in a Single-Center Cohort
Background and Objectives: The global resurgence of syphilis has been accompanied by an increasing number of ocular syphilis cases. Ocular syphilis can occur at any stage of infection and has diverse clinical manifestations, making diagnosis challenging. Materials and Methods: We retrospectively reviewed 21 adults diagnosed with ocular syphilis at a tertiary referral center between 2018 and 2023. Diagnosis was based on compatible ophthalmologic findings, together with positive treponemal serology. Demographic, clinical, ophthalmologic, laboratory, cerebrospinal fluid (CSF), imaging, and treatment data were analyzed. Results: A total of 21 patients (30 eyes) were included. The majority were male (87%), with a median age of 44 years, and bilateral involvement occurred in 43% of patients. Blurred vision and decreased visual acuity were the most common presenting symptoms (80%). Uveitis (68.4%), predominantly posterior, and optic neuritis (42.1%) were the most frequent ophthalmologic findings. Serum VDRL was negative in 5 of 21 patients despite positive treponemal serology. Among the 14 patients who underwent lumbar puncture, half had normal cerebrospinal fluid findings. All patients received neurosyphilis-directed antimicrobial therapy. The mean baseline BCVA was 0.38 ± 0.30 logMAR (range, 0–1), improving to 0.16 ± 0.28 logMAR (range, 0–1) at the final follow-up. The improvement in BCVA following treatment was statistically significant (p < 0.001). No eye showed deterioration in BCVA after treatment; visual acuity either improved or remained stable in all eyes. Additionally, all cases of uveitis and optic neuropathy achieved clinical remission during follow-up. Conclusions: Ocular syphilis remains a diagnostic challenge because of its heterogeneous clinical manifestations and the occurrence of negative serum VDRL results or normal cerebrospinal fluid findings in patients who underwent lumbar puncture. These findings highlight the limitations of relying solely on non-treponemal serology or cerebrospinal fluid analysis when evaluating patients with suspected ocular syphilis.
Open AccessOcular Syphilis in the Era of Resurgence: Clinical Characteristics and Diagnostic Challenges in a Single-Center Cohort
Background and Objectives: The global resurgence of syphilis has been accompanied by an increasing number of ocular syphilis cases. Ocular syphilis can occur at any stage of infection and has diverse clinical manifestations, making diagnosis challenging. Materials and Methods: We retrospectively reviewed 21 adults diagnosed with ocular syphilis at a tertiary referral center between 2018 and 2023. Diagnosis was based on compatible ophthalmologic findings, together with positive treponemal serology. Demographic, clinical, ophthalmologic, laboratory, cerebrospinal fluid (CSF), imaging, and treatment data were analyzed. Results: A total of 21 patients (30 eyes) were included. The majority were male (87%), with a median age of 44 years, and bilateral involvement occurred in 43% of patients. Blurred vision and decreased visual acuity were the most common presenting symptoms (80%). Uveitis (68.4%), predominantly posterior, and optic neuritis (42.1%) were the most frequent ophthalmologic findings. Serum VDRL was negative in 5 of 21 patients despite positive treponemal serology. Among the 14 patients who underwent lumbar puncture, half had normal cerebrospinal fluid findings. All patients received neurosyphilis-directed antimicrobial therapy. The mean baseline BCVA was 0.38 ± 0.30 logMAR (range, 0–1), improving to 0.16 ± 0.28 logMAR (range, 0–1) at the final follow-up. The improvement in BCVA following treatment was statistically significant (p < 0.001). No eye showed deterioration in BCVA after treatment; visual acuity either improved or remained stable in all eyes. Additionally, all cases of uveitis and optic neuropathy achieved clinical remission during follow-up. Conclusions: Ocular syphilis remains a diagnostic challenge because of its heterogeneous clinical manifestations and the occurrence of negative serum VDRL results or normal cerebrospinal fluid findings in patients who underwent lumbar puncture. These findings highlight the limitations of relying solely on non-treponemal serology or cerebrospinal fluid analysis when evaluating patients with suspected ocular syphilis.
- Open Access
- 13 April 2026
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 19 (2) , 385-389
Hepatitis A seroprevalence in patients with chronic hepatitis B and C at the initiation of treatment
Purpose: Hepatitis A is a vaccine-preventable disease that may follow a more severe course and can lead to fulminant hepatitis in patients with chronic hepatitis. The aim of this study is to determine the seroprevalence of hepatitis A in patients with chronic hepatitis B and C, and to assess the need for hepatitis A vaccination.Materials and methods: A total of 885 adult patients with chronic hepatitis B and C, who had not previously received hepatitis A vaccination and in whom antiviral therapy was initiated between January 2008 and December 2020, were included in the study. Immunity against hepatitis A was assessed at the time of diagnosis by measuring Anti-HAV IgG using the Microparticle Enzyme Immunoassay (MEIA; AxSYM-HAVAB 2.0, ABBOTT) method.Results: The seroprevalence of hepatitis A was 92.7% among 789 patients with chronic hepatitis B and 96 patients with chronic hepatitis C; it was determined to be 94% in patients with chronic hepatitis B and 83% in patients with chronic hepatitis C. While 78% of anti-HAV IgG seronegativity was detected in individuals under 30 years of age, 90% of seronegative cases were under 40. Seropositivity approached 100% in those over 50 years of age; however, a 64-year-old man and a 68-year-old woman with chronic hepatitis C were not immune to hepatitis A.Conclusion: Since hepatitis A superinfection in patients with chronic hepatitis B and C may follow a severe course and lead to a fulminant course, it should be kept in mind that hepatitis A seroprevalence is low, particularly in patients under 30 years of age. However, although the rate decreases with age in adult patients, seronegativity may be detected at any age; therefore, Anti-HAV IgG should be evaluated at the time of diagnosis in all patients with chronic hepatitis, and those found to be negative should be vaccinated against hepatitis A.
- 13 April 2026
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 19 (2) , 385-389
Open AccessHepatitis A seroprevalence in patients with chronic hepatitis B and C at the initiation of treatment
Purpose: Hepatitis A is a vaccine-preventable disease that may follow a more severe course and can lead to fulminant hepatitis in patients with chronic hepatitis. The aim of this study is to determine the seroprevalence of hepatitis A in patients with chronic hepatitis B and C, and to assess the need for hepatitis A vaccination.Materials and methods: A total of 885 adult patients with chronic hepatitis B and C, who had not previously received hepatitis A vaccination and in whom antiviral therapy was initiated between January 2008 and December 2020, were included in the study. Immunity against hepatitis A was assessed at the time of diagnosis by measuring Anti-HAV IgG using the Microparticle Enzyme Immunoassay (MEIA; AxSYM-HAVAB 2.0, ABBOTT) method.Results: The seroprevalence of hepatitis A was 92.7% among 789 patients with chronic hepatitis B and 96 patients with chronic hepatitis C; it was determined to be 94% in patients with chronic hepatitis B and 83% in patients with chronic hepatitis C. While 78% of anti-HAV IgG seronegativity was detected in individuals under 30 years of age, 90% of seronegative cases were under 40. Seropositivity approached 100% in those over 50 years of age; however, a 64-year-old man and a 68-year-old woman with chronic hepatitis C were not immune to hepatitis A.Conclusion: Since hepatitis A superinfection in patients with chronic hepatitis B and C may follow a severe course and lead to a fulminant course, it should be kept in mind that hepatitis A seroprevalence is low, particularly in patients under 30 years of age. However, although the rate decreases with age in adult patients, seronegativity may be detected at any age; therefore, Anti-HAV IgG should be evaluated at the time of diagnosis in all patients with chronic hepatitis, and those found to be negative should be vaccinated against hepatitis A.
- Open Access
- 20 February 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (2) , 229
Prospective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Onset Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)-producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aims to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between 1 October 2022 and 29 February 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, hospitalization more than one month prior, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility profiles and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p < 0.05 considered statistically significant. Results: Escherichia coli (n = 142) and Klebsiella spp. (n = 43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). In the multivariate logistic regression analysis, male sex (p = 0.038) and hospitalization more than one month prior (p = 0.016) were identified as independent risk factors for ESBL positivity, while prior antibiotic use in the last three months showed a borderline association (p = 0.055) and did not reach statistical significance. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p < 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.
- 20 February 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (2) , 229
Open AccessProspective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Onset Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)-producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aims to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between 1 October 2022 and 29 February 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, hospitalization more than one month prior, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility profiles and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p < 0.05 considered statistically significant. Results: Escherichia coli (n = 142) and Klebsiella spp. (n = 43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). In the multivariate logistic regression analysis, male sex (p = 0.038) and hospitalization more than one month prior (p = 0.016) were identified as independent risk factors for ESBL positivity, while prior antibiotic use in the last three months showed a borderline association (p = 0.055) and did not reach statistical significance. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p < 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.
- Open Access
- 15 January 2026
- Published by MDPI AG in Preprints.org
Prospective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Acquired Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)–producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aimed to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between October 1, 2022, and February 29, 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, recent hospitalization, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility pro-files and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p< 0.05 considered statistically significant. Results: Escherichia coli (n=142) and Klebsiella spp. (n=43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). Male sex (p=0.007), history of urinary intervention (p=0.019), hospitalization within the previous month (p< 0.001), and antibiotic use in the last three months (p=0.002) were identified as significant risk factors for ESBL positivity. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p< 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.
- 15 January 2026
- Published by MDPI AG in Preprints.org
Open AccessProspective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Acquired Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)–producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aimed to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between October 1, 2022, and February 29, 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, recent hospitalization, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility pro-files and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p< 0.05 considered statistically significant. Results: Escherichia coli (n=142) and Klebsiella spp. (n=43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). Male sex (p=0.007), history of urinary intervention (p=0.019), hospitalization within the previous month (p< 0.001), and antibiotic use in the last three months (p=0.002) were identified as significant risk factors for ESBL positivity. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p< 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.
- 12 September 2024
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 29 (3) , 388-392
Hafif/Orta ve Ağır COVID-19 Pnömonili Hastalarda Akciğer Tutulumunun Yaygınlığı ve Kortikosteroid Tedavi Gereksinimi
- 12 September 2024
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 29 (3) , 388-392
Hafif/Orta ve Ağır COVID-19 Pnömonili Hastalarda Akciğer Tutulumunun Yaygınlığı ve Kortikosteroid Tedavi Gereksinimi
- Open Access
- 1 July 2024
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 15 (2) , 248-255
Clinical and Radiological Features of Pyogenic and Brucellar Spondylodiscitis
Aim: Since spondylodiscitis continues to be seen with increasing incidence; thus, starting antibiotherapy targeted towards the etiological agent is crucial for reducing complications and mortality. This study aimed to determine the clinical and radiological characteristics of spondylodiscitis’ causative microorganisms. Material and Methods: Patients hospitalized in the Department of Infectious Diseases and Clinical Microbiology with a diagnosis of spondylodiscitis between 2015 and 2023 were retrospectively evaluated. Results: Low back pain was present in 97.5% of the total 40 patients as the most common symptom. Tissue biopsy culture results were obtained for 21 (52.5%) patients, with culture positivity observed in five (12.5%) patients. Consumption of raw milk/dairy products in the anamnesis and fever were found to be statistically significantly higher in patients with brucellosis (p < 0.001, p = 0.015), whereas neurological deficits were significantly higher in the pyogenic group (p = 0.007). No significant differences were observed between the pyogenic and brucella spondylodiscitis groups in terms of laboratory parameters (sedimentation rate, C-reactive protein, white blood cell count) and magnetic resonance imaging findings. Conclusion: Since no distinctive clinical and radiological parameters were identified for distinguishing between brucellar and pyogenic spondylodiscitis, serological tests for brucellosis should be investigated when considering the diagnosis, particularly in endemic regions. In cases of pyogenic spondylodiscitis, empirical antibiotic use prior to pathogen isolation may lead to delays in diagnosis and appropriate treatment, potentially resulting in complications such as neurological deficits. Therefore, interventional methods for tissue biopsy culture should be planned before antibiotherapy, especially in patients who do not immediately require antibiotherapy.
- 1 July 2024
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 15 (2) , 248-255
Open AccessClinical and Radiological Features of Pyogenic and Brucellar Spondylodiscitis
Aim: Since spondylodiscitis continues to be seen with increasing incidence; thus, starting antibiotherapy targeted towards the etiological agent is crucial for reducing complications and mortality. This study aimed to determine the clinical and radiological characteristics of spondylodiscitis’ causative microorganisms. Material and Methods: Patients hospitalized in the Department of Infectious Diseases and Clinical Microbiology with a diagnosis of spondylodiscitis between 2015 and 2023 were retrospectively evaluated. Results: Low back pain was present in 97.5% of the total 40 patients as the most common symptom. Tissue biopsy culture results were obtained for 21 (52.5%) patients, with culture positivity observed in five (12.5%) patients. Consumption of raw milk/dairy products in the anamnesis and fever were found to be statistically significantly higher in patients with brucellosis (p < 0.001, p = 0.015), whereas neurological deficits were significantly higher in the pyogenic group (p = 0.007). No significant differences were observed between the pyogenic and brucella spondylodiscitis groups in terms of laboratory parameters (sedimentation rate, C-reactive protein, white blood cell count) and magnetic resonance imaging findings. Conclusion: Since no distinctive clinical and radiological parameters were identified for distinguishing between brucellar and pyogenic spondylodiscitis, serological tests for brucellosis should be investigated when considering the diagnosis, particularly in endemic regions. In cases of pyogenic spondylodiscitis, empirical antibiotic use prior to pathogen isolation may lead to delays in diagnosis and appropriate treatment, potentially resulting in complications such as neurological deficits. Therefore, interventional methods for tissue biopsy culture should be planned before antibiotherapy, especially in patients who do not immediately require antibiotherapy.
- 25 June 2024
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 29 (2) , 211-217
Kuduz Riskli Temas Olgu Kayıtlarının Dokuz Yıllık Retrospektif Değerlendirilmesi: Tek Merkez Deneyimi
- 25 June 2024
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 29 (2) , 211-217
Kuduz Riskli Temas Olgu Kayıtlarının Dokuz Yıllık Retrospektif Değerlendirilmesi: Tek Merkez Deneyimi
- 22 December 2023
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 28 (4) , 583-595
Influenza
- 22 December 2023
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 28 (4) , 583-595
Influenza
- Open Access
- 30 April 2023
- Published by MediHealth Academy in Journal of Translational and Practical Medicine
- Vol. 2 (1) , 26-29
A hemodialysis case with fungemia due to Candida parapsilosis after COVID-19 infection
Bacterial and fungal infections may emerge with or following COVID-19 infection. Corticosteroids, antibiotics, and other therapies utilized in severe cases of COVID-19 pneumonia may pose a risk for fungal infections. In this paper, we present the case of a 59-year-old female patient with underlying chronic renal failure and diabetes who received long-term corticosteroid therapy for COVID-19 pneumonia and subsequently developed fungemia and catheter infection due to Candida parapsilosis. We removed her subclavian catheter and administered amphotericin -B therapy for 37 days. Overall, we recommend keeping in mind that opportunistic fungal infections may emerge in patients receiving long-term immunosuppressive drug therapy due to COVID-19 with risk factors such as hemodialysis, central venous catheter use, and broad-spectrum antibiotic use.
- 30 April 2023
- Published by MediHealth Academy in Journal of Translational and Practical Medicine
- Vol. 2 (1) , 26-29
Open AccessA hemodialysis case with fungemia due to Candida parapsilosis after COVID-19 infection
Bacterial and fungal infections may emerge with or following COVID-19 infection. Corticosteroids, antibiotics, and other therapies utilized in severe cases of COVID-19 pneumonia may pose a risk for fungal infections. In this paper, we present the case of a 59-year-old female patient with underlying chronic renal failure and diabetes who received long-term corticosteroid therapy for COVID-19 pneumonia and subsequently developed fungemia and catheter infection due to Candida parapsilosis. We removed her subclavian catheter and administered amphotericin -B therapy for 37 days. Overall, we recommend keeping in mind that opportunistic fungal infections may emerge in patients receiving long-term immunosuppressive drug therapy due to COVID-19 with risk factors such as hemodialysis, central venous catheter use, and broad-spectrum antibiotic use.